Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma

Leukemia

Volumn 23, Issue 5, 2009, Pages 961-970

  Raje, N ^a,b   Hideshima, T ^a   Mukherjee, S ^b   Raab, M ^a   Vallet, S ^a,b   Chhetri, S ^a   Cirstea, D ^a   Pozzi, S ^a   Mitsiades, C ^a   Rooney, M ^a   Kiziltepe, T ^a   Podar, K ^a   Okawa, Y ^a   Ikeda, H ^a   Carrasco, R ^a   Richardson, P G ^a   Chauhan, D ^a   Munshi, N C ^a   Sharma, S ^c   Parikh, H ^c   Chabner, B ^b   Scadden, D ^b   Anderson, K C ^a   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Piramal Enterprises Limited   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CASPASE; CYCLIN D; CYCLIN DEPENDENT KINASE INHIBITOR; INTERLEUKIN 6; MESSENGER RNA; P 276 00; PROTEASOME; RETINOBLASTOMA 1 PROTEIN; RETINOBLASTOMA PROTEIN; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER RECURRENCE; CANCER SURVIVAL; CELL ADHESION; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; DRUG TARGETING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MALE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REFRACTORY PERIOD; STROMA CELL; WEIGHT REDUCTION;

EID: 67349099081     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.378     Document Type: Article

References (37)

1. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: Clinical applications. Blood 2004; 104: 607-618.
2. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007; 7: 585-598.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
4. Raje N, Anderson K. Thalidomide - a revival story. N Engl J Med 1999; 341: 1606-1609.
5. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.
6. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617.
7. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.
8. Raje N, Hideshima T, Anderson KC. Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma. Expert Rev Anticancer Ther 2006; 6: 1239-1247.
9. Harousseau JL, Moreau P. Evolving role of stem cell transplantation in multiple myeloma. Clin Lymphoma Myeloma 2005; 6: 89-95.
10. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516-2520.
11. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy Jr J. Cyclin D dysregulation: An early and unifying pathogenic event in multiple myeloma. Blood 2005; 106: 296-303.
12. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005; 23: 6333-6338.
13. Shaughnessy Jr JD, Barlogie B. Using genomics to identify high-risk myeloma after autologous stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 77-80.
14. Kuehl WM, Bergsagel PL. Early genetic events provide the basis for a clinical classification of multiple myeloma. Am Soc Hematol Educ Program 2005, 346-352.
15. Agnelli L, Bicciato S, Mattioli M, Fabris S, Intini D, Verdelli D et al. Molecular classification of multiple myeloma: A distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations. J Clin Oncol 2005; 23: 7296-7306.
16. Fonseca R, Bailey RJ, Ahmann GJ, Rajkumar SV, Hoyer JD, Lust JA et al Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 2002; 100: 1417-1424.
17. Fonseca R, Blood EA, Oken MM, Kyle RA, Dewald GW, Bailey RJ et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood 2002; 99: 3735-3741.
18. 2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther 2007; 6 926-934.
19. Joshi KS, Rathos MJ, Joshi RD, Sivakumar M, Mascarenhas M, Kamble S et al. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00. Mol Cancer Ther 2007; 6: 918-925.
20. Tai YT, Teoh G, Shima Y, Chauhan D, Treon SP, Raje N et al. Isolation and characterization of human multiple myeloma cell enriched populations. J Immunol Methods 2000; 235: 11-19.
21. Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 2006; 9: 313-325.
22. Nelsen CJ, Kuriyama R, Hirsch B, Negron VC, Lingle WL, Goggin MM et al. Short term cyclin D1 overexpression induces centro-some amplification, mitotic spindle abnormalities, and aneuploidy. J Biol Chem 2005; 280: 768-776.
23. Raje N, Kumar S, Hideshima T, Ishitsuka K, Chauhan D, Mitsiades C et al. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood 2004; 104: 4188-4193.
24. Raje N, Kumar S, Hideshima T, Roccaro A, Ishitsuka K, Yasui H et al Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood 2005; 106: 1042-1047.
25. Ishii Y, Pirkmaier A, Alvarez JV, Frank DA, Keselman I, Logothetis D et al. Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model. J Natl Cancer Inst 2006; 98: 1238-1247.
26. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
27. Toogood PL. Cyclin-dependent kinase inhibitors for treating cancer. Med Res Rev 2001; 21: 487-498.
28. Chen-Kiang S. Cell-cycle control of plasma cell differentiation and tumorigenesis. Immunol Rev 2003; 194: 39-47.
29. Ely S, Di Liberto M, Niesvizky R, Baughn LB, Cho HJ, Hatada EN et al Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma. Cancer Res 2005; 65: 11345-11353.
30. Swanton C. Cell-cycle targeted therapies. Lancet Oncol 2004; 5 27-36.
31. Malumbres M, Pevarello P, Barbacid M, Bischoff JR. CDK inhibitors in cancer therapy: What is next? Trends Pharmacol Sci 2008; 1: 16-21.
32. Krieger S, Gauduchon J, Roussel M, Troussard X, Sola B. Relevance of cyclin D1b expression and CCND1 polymorphism in the pathogenesis of multiple myeloma and mantle cell lymphoma. BMC Cancer 2006; 6 238.
33. Kozar K, Sicinski P. Cell cycle progression without cyclin D-CDK4 and cyclin D-CDK6 complexes. Cell Cycle 2005; 4: 388-391.
34. Kozar K, Ciemerych MA, Rebel VI, Shigematsu H, Zagozdzon A, Sicinska E et al. Mouse development and cell proliferation in the absence of D-cyclins. Cell 2004; 118: 477-491.
35. Malumbres M, Sotillo R, Santamaria D, Galan J, Cerezo A, Ortega S et al. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 2004; 118: 493-504.
36. Blagosklonny MV. Flavopiridol, an inhibitor of transcription: implications, problems and solutions. Cell Cycle 2004; 3: 1537-1542.
37. 1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res 2006; 66 7661-7667.